**Supplemental Materials**

**Figure S1.** Prevention of oxaliplatin-induced neurotoxicity by duloxetine in vitro------------------------------------------------------------------------------------------------2

**Figure S2.** Prevention of paclitaxel-induced neurotoxicity by duloxetine in vitro------------------------------------------------------------------------------------------------2

**Figure S3.** Impact of duloxetine on body weight of ICR mice treated with or without OXA or PTX--------------------------------------------------------------------------------------3

**Figure S4.** Effect of duloxetine on phosphorylation of p38 MAPK and ERK1/2 expression in the neuropathic mouse DRG following oxaliplatin treatment-------------3

**Figure S5.** Effect of duloxetine on NF-κB, phosphorylation of p38 MAPK and ERK1/2 expression in the neuropathic mouse DRG following PTX treatment---------4

**Figure S6.** Effect of duloxetine on IENF retraction induced by OXA or PTX. --------4

**Figure S7.** Effect of duloxetine on serotonin or NE level in DRG cell culture. --------5

**Figure S8.** Effect of duloxetine on DRG-----------------------------------------------------5

**Table S1.** Cytokine changes in mice following chemotherapy and duloxetine treatments -----------------------------------------------------------------------------------------5

ATP-OXA副本

Figure S1. **Prevention of oxaliplatin-induced neurotoxicity by duloxetine in vitro. Relatived to Figure 1.**

(A) Primary rat DRG neuron cells were exposed to various concentrations of oxaliplatin for 48 hours and ATP levels was measured (\*p < 0.05 vs control). (B) Primary rat DRG neuron cells were exposed to oxaliplatin with various concentrations of duloxetine for 48 hours and ATP levels were measured (\* p < 0.05 vs control; # p < 0.05 vs oxaliplatin alone). All the data are presented as mean ± SEM for each experiment (n = 4).




Figure S2. **Prevention of paclitaxel-induced neurotoxicity by duloxetine in vitro.** **Relatived to Figure 1.**

(A) Primary rat DRG neuron cells were exposed to various concentrations of paclitaxel for 24 hours and cell viability was measured (\* p < 0.05 compared to control). (B) Primary rat DRG neuron cells were exposed to paclitaxel with various concentrations of duloxetine for 24 hours and ATP levels were measured (\*\*\* p < 0.0001 vs control; # p < 0.05 vs paclitaxel alone). All the data are presented as mean ± SEM for each experiment (n= 4).




Figure S3. **Impact of duloxetine on body weight of ICR mice treated with or without OXA or PTX**.

There was no significant difference in the body weight after daily administration of duloxetine (30 mg/kg) in animals treated with vehicle or chemotherapeutic drugs (OXA and PTX).




Figure S4. **Effect of duloxetine on phosphorylation of p38 MAPK and ERK1/2 expression in the neuropathic mouse DRG following oxaliplatin treatment**. **Relatived to Figure 6.**

WB PTX

Figure S5. **Effect of duloxetine on NF-κB, phosphorylation of p38 MAPK and ERK1/2 expression in the neuropathic mouse DRG following PTX treatment**. **Relatived to Figure 7.**




Figure S6.**Effect of duloxetine on IENF retraction induced by OXA or PTX. Relatived to Figure 5.**




Figure S7. **Effect of duloxetine on serotonin or NE level in the DRG cell culture**. (ELISA) DRG neuronal cells were treated with (or without) PTX (300 nM) and duloxetine (300 nM) for 24 h, then serotonin and NE level were measured using Elisa kit.




Figure S8. **Effect of duloxetine on DRG** Primary rat DRG neuron cells were exposed to various concentrations of duloxetine for 24 hours and ATP level was measured.

Table S1. **Cytokine changes in mice following chemotherapy and duloxetine treatments (pg/mL).**

The table shows the mean and SEM (standard error of the mean) for IL-1β, IL-6, TNF-α and NGF concentrations (pg/mL) in mouse blood samples. (n = 5, *\* p* <0.05 vs control, *# p* <0.05 vs OXA alone, *^ p* <0.05 vs PTX alone)

